Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Anatomic Stage II Breast Cancer AJCC v8 × trastuzumab biosimilar HLX02 × Clear all

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lung Neoplasms 1 Inflammatory Breast Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Bladder Urothelial Carcinoma 1 Anatomic Stage II Breast Cancer AJCC v8 1

Interventions

tucatinib 1 trastuzumab biosimilar HLX02 1 ribociclib 1 pertuzumab 1 Trastuzumab 1 PF-05280014 1 Ontruzant 1 Ogivri 1 Fulvestrant 1 Docetaxel 1 Carboplatin 1 2C4 antibody 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05319873 2025-05-13

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

Jonsson Comprehensive Cancer Center

Phase 1/2 Recruiting

Anatomic Stage II Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon ⚡